MiR-487a resensitizes mitoxantrone (MX)-resistant breast cancer cells (MCF-7/MX) to MX by targeting breast cancer resistance protein (BCRP/ABCG2)

Cancer Letters

Volumn 339, Issue 1, 2013, Pages 107-115

  Ma, Meng Tao ^a   He, Miao ^a   Wang, Yan ^a   Jiao, Xu Yang ^a   Zhao, Lin ^a   Bai, Xue Feng ^a   Yu, Zhao Jin ^a   Wu, Hui Zhe ^a   Sun, Ming Li ^a   Song, Zhi Guo ^a   Wei, Min Jie ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

BCRP; Breast cancer; MiR 487a; Multidrug resistance

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; ETOPOSIDE; MICRORNA; MICRORNA 487A; MITOXANTRONE; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CELL STRAIN MCF 7; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; TREATMENT RESPONSE;

BCRP; BREAST CANCER; MIR-487A; MULTIDRUG RESISTANCE;

3' UNTRANSLATED REGIONS; ANIMALS; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BREAST NEOPLASMS; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MCF-7 CELLS; MICE; MICRORNAS; MITOXANTRONE; NEOPLASM PROTEINS; RNA INTERFERENCE; TRANSPLANTATION, HETEROLOGOUS;

EID: 84883449522     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.07.016     Document Type: Article

References (39)

1. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN. Int. J. Cancer 2008, 127(2010):2893-2917.
2. Marquette C., Nabell L. Chemotherapy-resistant metastatic breast cancer. Curr. Treat. Options Oncol. 2012, 13:263-275.
3. Ni Z., Bikadi Z., Rosenberg M.F., Mao Q. Structure and function of the human breast cancer resistance protein (BCRP/ABCG2). Curr. Drug Metab. 2010, 11:603-617.
4. Doyle L.A., Yang W., Abruzzo L.V., Krogmann T., Gao Y., Rishi A.K., Ross D.D. A multidrug resistance transporter from human MCF 7 breast cancer cells. Proc. Nat. Acad. Sci. USA 1998, 95:15665-15670.
5. Krishnamachary N., Center M.S. The MRP gene associated with a non-P-glycoprotein multidrug resistance encodes a 190-kDa membrane bound glycoprotein. Cancer Res. 1993, 53:3658-3661.
6. Kartner N., Riordan J.R., Ling V. Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science 1983, 221:1285-1288.
7. Scheffer G.L., Wijngaard P.L., Flens M.J., Izquierdo M.A., Slovak M.L., Pinedo H.M., Meijer C.J., Clevers H.C., Scheper R.J. The drug resistance-related protein LRP is the human major vault protein. Nat. Med. 1995, 1:578-582.
8. Maliepaard M., van Gastelen M.A., de Jong L.A., Pluim D., van Waardenburg R.C., Ruevekamp-Helmers M.C., Floot B.G., Schellens J.H. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res. 1999, 59:4559-4563.
9. Yang C.H., Schneider E., Kuo M.L., Volk E.L., Rocchi E., Chen Y.C. BCRP/MXR/ABCP expression in topotecan-resistant human breast carcinoma cells. Biochem. Pharmacol. 2000, 60:831-837.
10. Kawabata S., Oka M., Shiozawa K., Tsukamoto K., Nakatomi K., Soda H., Fukuda M., Ikegami Y., Sugahara K., Yamada Y., Kamihira S., Doyle L.A., Ross D.D., Kohno S. Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells. Biochem. Biophys. Res. Commun. 2001, 280:1216-1223.
11. Robey R.W., Medina-Perez W.Y., Nishiyama K., Lahusen T., Miyake K., Litman T., Senderowicz A.M., Ross D.D., Bates S.E. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells. Clin. Cancer Res. 2001, 7:145-152.
12. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
13. To K.K., Zhan Z., Litman T., Bates S.E. Regulation of ABCG2 expression at the 30 untranslated region of its mRNA through modulation of transcript stability and protein translation by a putativemicroRNA in the S1 colon cancer cell line. Mol. Cell. Biol. 2008, 28:5147-5161.
14. Wang F., Xue X., Wei J., An Y., Yao J., Cai H., Wu J., Dai C., Qian Z., Xu Z., Miao Y. Hsa-miR-520h down-regulates ABCG2 in pancreatic cancer cells to inhibit migration, invasion, and side populations. Br. J. Cancer 2010, 103:567-574.
15. Pan Y.Z., Morris M.E., Yu A.M. MicroRNA-328 negatively regulates the expression of breast cancer resistance protein (BCRP/ABCG2) in human cancer cells. Mol. Pharmacol. 2009, 75:1374-1379.
16. Liang Z., Wu H., Xia J., Li Y., Zhang Y., Huang K., Wagar N., Yoon Y., Cho H.T., Scala S., Shim H. Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem. Pharmacol. 2010, 79:817-824.
17. Liu F., Fan D., Qi J., Zhu H., Zhou Y., Yang C., Zhu Z., Xiong D. Co-expression of cytokeratin 8 and breast cancer resistant protein indicates a multifactorial drug-resistant phenotype in human breast cancer cell line. Life Sci. 2008, 83:496-501.
18. Nikitina E.G., Urazova L.N., Stegny V.N. MicroRNAs and human cancer. Exp. Oncol. 2012, 34:2-8.
19. Zhang B., Pan X., Cobb G.P., Anderson T.A. MicroRNAs as oncogenes and tumor suppressors. Dev. Biol. 2007, 302:1-12.
20. Majumder S., Jacob S.T. Emerging role of microRNAs in drug-resistant breast cancer. Gene Expr. 2011, 15:141-151.
21. Giovannetti E., Erozenci A., Smit J., Danesi R., Peters G.J. Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice. Crit. Rev. Oncol. Hematol. 2012, 81:103-122.
22. Kovalchuk O., Filkowski J., Meservy J., Ilnytskyy Y., Tryndyak V.P., Chekhun V.F., Pogribny I.P. Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol. Cancer Ther. 2008, 7:2152-2159.
23. Pogribny I.P., Filkowski J.N., Tryndyak V.P., Golubov A., Shpyleva S.I., Kovalchuk O. Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin. Int. J. Cancer 2010, 127:1785-1794.
24. Feng B., Wang R., Chen L.B. MiR-100 resensitizes docetaxel-resistant human lung adenocarcinoma cells (SPC-A1) to docetaxel by targeting Plk1. Cancer Lett. 2012, 317:184-191.
25. Tsubaki M., Satou T., Itoh T., Imano M., Komai M., Nishinobo M., Yamashita M., Yanae M., Yamazoe Y., Nishida S. Overexpression of MDR1 and survivin, and decreased Bim expression mediate multidrug-resistance in multiple myeloma cells. Leuk. Res. 2012, 36:1315-1322.
26. Chen Z.S., Tiwari A.K. Multidrug resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic diseases. FEBS J. 2011, 278:3226-3245.
27. Ross D.D., Yang W., Abruzzo L.V., Dalton W.S., Schneider E., Lage H., Dietel M., Greenberger L., Cole S.P., Doyle L.A. Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J. Nat. Cancer Inst. 1999, 91:429-433.
28. Lee E., Lim S.J. The association of increased lung resistance protein expression with acquired etoposide resistance in human H460 lung cancer cell lines. Arch. Pharm. Res. 2006, 29:1018-1023.
29. Bao L., Hazari S., Mehra S., Kaushal D., Moroz K., Dash S. Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298. Am. J. Pathol. 2012, 180:2490-2503.
30. Kalalinia F., Elahian F., Behravan J. Potential role of cyclooxygenase-2 on the regulation of the drug efflux transporter ABCG2 in breast cancer cell lines. J. Cancer Res. Clin. Oncol. 2011, 137:321-330.
31. Hou J., Lin L., Zhou W., Wang Z., Ding G., Dong Q., Qin L., Wu X., Zheng Y., Yang Y., Tian W., Zhang Q., Wang C., Zhang Q., Zhuang S.M., Zheng L., Liang A., Tao W., Cao X. Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell 2011, 19:232-243.
32. Eulalio A., Huntzinger E., Izaurralde E. Getting to the root of miRNA-mediated gene silencing. Cell 2008, 132:9-14.
33. Filipowicz W., Bhattacharyya S.N., Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight?. Nat. Rev. Genet. 2008, 9:102-114.
34. Fabian M.R., Sonenberg N., Filipowicz W. Regulation of mRNA translation and stability by microRNAs. Annu. Rev. Biochem. 2010, 79:351-379.
35. Sorrentino A., Liu C.G., Addario A., Peschle C., Scambia G., Ferlini C. Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol. Oncol. 2008, 111:478-486.
36. Zhao J.J., Lin J., Yang H., Kong W., He L., Ma X., Coppola D., Cheng J.Q. MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J. Biol. Chem. 2008, 283:31079-31086.
37. Kopp F., Oak P.S., Wagner E., Roidl A. MiR-200c sensitizes breast cancer cells to doxorubicin treatment by decreasing TrkB and Bmi1 expression. PLoS ONE 2012, 7:e50469.
38. Lim L.P., Lau N.C., Garrett-Engele P., Grimson A., Schelter J.M., Castle J., Bartel D.P., Linsley P.S., Johnson J.M. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 2005, 433:769-773.
39. Krek A., Grün D., Poy M.N., Wolf R., Rosenberg L., Epstein E.J., MacMenamin P., da Piedade I., Gunsalus K.C., Stoffel M., Rajewsky N. Combinatorial microRNA target predictions. Nat. Genet. 2005, 37:495-500.